Co-Authors
This is a "connection" page, showing publications co-authored by JEFFREY J MOLLDREM and ELIZABETH SHPALL.
Connection Strength
1.924
-
Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo. Cytotherapy. 2024 Nov; 26(11):1331-1340.
Score: 0.242
-
Hu8F4-CAR T cells with mutated Fc spacer segment improve target-specificity and mediate anti-leukemia activity in vivo. Res Sq. 2024 Feb 19.
Score: 0.236
-
PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy. 2016 08; 18(8):995-1001.
Score: 0.140
-
A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016 08; 18(8):985-994.
Score: 0.138
-
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
Score: 0.127
-
Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med. 2014 Dec; 3(12):1435-43.
Score: 0.124
-
Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014 Jan; 16(1):90-100.
Score: 0.115
-
Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.
Score: 0.109
-
Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007 Dec 15; 110(13):4543-51.
Score: 0.075
-
Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy. 2006; 8(2):149-57.
Score: 0.067
-
Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe. 2024 Sep 11; 32(9):1621-1636.e6.
Score: 0.061
-
Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq. 2023 Jan 31.
Score: 0.055
-
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445.
Score: 0.054
-
Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022 09 29; 185(20):3705-3719.e14.
Score: 0.054
-
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719.
Score: 0.049
-
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
Score: 0.042
-
Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res. 2019 04 15; 25(8):2610-2620.
Score: 0.041
-
Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy. 2018 08; 20(8):1089-1101.
Score: 0.040
-
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016 07 14; 128(2):297-312.
Score: 0.035
-
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014 Sep 25; 124(13):2034-45.
Score: 0.030
-
Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One. 2012; 7(12):e51390.
Score: 0.027
-
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011 Nov 24; 118(22):5957-64.
Score: 0.025
-
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
Score: 0.021
-
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007 Jul; 40(2):125-36.
Score: 0.018